Reprocell Co. acquires development and sales rights in Japan for Stemchymal, a cell product for the treatment of Polyglutamine Spinocerebellar Ataxia (PolyQ SCAs)

The cellular drug was developed by Taiwan’s Steminent Biotherapeutics Co. and is derived from adipose cells. Clinical trials in Japan will begin in autumn 2017.

Nikkei Biotech news release, November 15, 2016

Most popular posts: